• In early 2026, Harrow reported record Q4 and FY2025 results with strong revenue growth and a shift to positive operating cash flow, but also missed EBITDA and EPS expectations because of a one-time R&D charge and higher commercial spending.
• Management tempered its 2026 guidance while accelerating investment behind products such as VEVYE, TRIESENCE, BYOOVIZ, and BYQLOVI, signaling a deliberate trade-off between near-term profitability and building a broader ophthalmic portfolio.
• We’ll now examine how Harrow’s more cautious 2026 guidance, paired with stepped-up sales and R&D investment, reshapes its investment narrative.

Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.

Harrow Investment Narrative Recap

To own Harrow, you need to believe its expanding ophthalmic portfolio can justify today’s valuation and fund a path to sustained profitability, despite current reliance on a few key brands. The latest results, with record 2025 revenue and a move to positive operating cash flow but more cautious 2026 guidance, do not materially change the near term catalyst around VEVYE and upcoming launches, though they do underline execution risk if newer products ramp more slowly than hoped.

The most relevant recent announcement here is Harrow’s 2026 revenue guidance of US$350 million to US$365 million, which reset expectations after the stock’s sharp pullback. This guidance frames how much investment the company is willing to put behind VEVYE, TRIESENCE, BYOOVIZ, and BYQLOVI in the next year, and it directly shapes how investors weigh today’s margin pressure against the potential payoff from these launches as the main catalysts ahead.

Yet underneath the promising growth story, investors should also be aware of the risk that tighter reimbursement or pricing pressure could...

Harrow's narrative projects $586.7 million revenue and $209.0 million earnings by 2028.

Uncover how Harrow's forecasts yield a $70.62 fair value, a 73% upside to its current price.

Exploring Other Perspectives

Some of the lowest analysts were already cautious, assuming Harrow would need about US$694.2 million of revenue and US$136.6 million of earnings by 2029, so this reset in guidance may reinforce their concern about how vulnerable those targets are to future pricing pressure and reimbursement risk.

Explore 3 other fair value estimates on Harrow - why the stock might be worth just $59.00!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Harrow research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free Harrow research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Harrow's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Find 50 companies with promising cash flow potential yet trading below their fair value.
• We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.